AMH Ovarian Reserve: Critical Findings in 4 Subgroups
An evidence synthesis on AMH ovarian reserve testing covering predictive value for IVF response, the POSEIDON 4-subgroup classification, comparison with FSH and antral follicle count, and counseling implications for fertility patients.
One-Minute Takeaway on AMH Ovarian Reserve
One-Minute Takeaway
- AMH ovarian reserve testing is a validated biomarker of antral follicle pool size and IVF stimulation response, with pooled meta-analytic AUC around 0.78 for poor response prediction.
- The POSEIDON criteria classify low-prognosis IVF patients into 4 subgroups based on age and ovarian reserve markers, structuring individualized stimulation strategy.
- The Steiner 2017 JAMA cohort established that AMH does not reliably predict natural fecundity in women without diagnosed infertility — a critical counseling point.
- AMH and antral follicle count have comparable predictive performance for IVF response; AMH offers practical advantages of cycle-independent sampling.
- Inter-assay variability remains a real-world limitation; threshold values must be referenced to the specific assay platform and local laboratory.
Why AMH Ovarian Reserve Testing Matters
AMH ovarian reserve testing has become a standard component of fertility evaluation over the past two decades. Anti-Müllerian hormone is produced by granulosa cells of preantral and small antral follicles and serves as a quantitative marker of the ovarian follicle pool. Levels decline progressively with age and are essentially undetectable after menopause.
The principal validated clinical role of AMH ovarian reserve testing is the prediction of response to controlled ovarian hyperstimulation in IVF. Pooled meta-analyses including the Broer 2011 systematic review and the Iliodromiti 2015 update establish AMH as a useful biomarker for both poor and hyper responders, with AUC values around 0.78 for poor response prediction.
The POSEIDON criteria (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number) introduced by Alviggi 2016 reframed management of low-prognosis IVF patients into four subgroups based on age and ovarian reserve markers. The framework structures stimulation strategy and counseling around AMH and antral follicle count combined with patient age.
A critical counseling distinction is that AMH ovarian reserve testing does not reliably predict natural fecundity. The Steiner 2017 JAMA study evaluated 750 women aged 30–44 without infertility and found that low AMH was not associated with reduced natural conception over 12 months. This finding underpins ASRM and ACOG cautions against using AMH as a fertility-prediction test in unselected women.
The 2020 ASRM Practice Committee opinion positions AMH and antral follicle count (AFC) as the preferred biomarkers of ovarian reserve, with day-3 FSH retaining a secondary role. Cycle-independent sampling for AMH offers practical advantages over FSH-based approaches that require synchronous early follicular phase blood draw.
What Evidence Was Reviewed
This synthesis draws on the Broer 2011 meta-analysis of AMH for hyper response prediction, the Broer 2009 individual patient data analysis comparing AMH and antral follicle count, the Broer 2013 IPD meta-analysis of added value over patient characteristics, the Iliodromiti 2015 update on technical performance, the Steiner 2017 JAMA prospective cohort on natural fecundity, the Alviggi 2016 and Esteves 2018 papers establishing the POSEIDON criteria, and the 2020 ASRM Practice Committee opinion on testing and interpreting ovarian reserve measures.
Together these sources include more than 25,000 women across diagnostic accuracy studies, prospective IVF cohorts, and fertility-without-infertility cohorts. Outcomes assessed include poor and hyper IVF response, ongoing pregnancy and live birth, natural cumulative conception over 6 to 12 months, and assay-related performance characteristics.
| Study / Source | Design | n | Question | Primary Outcome |
|---|---|---|---|---|
| Broer 2011 (Hum Reprod Update) | SR/MA | ~5,000 (pooled) | AMH/AFC for hyper response prediction | AUC for excessive response |
| Broer 2009 (Fertil Steril) | Individual patient data MA | 2,492 | AMH vs AFC for IVF response | AUC for poor and hyper response |
| Broer 2013 (Hum Reprod Update) | IPD MA | 4,089 | Added value of AMH/AFC over clinical predictors | Ovarian response and ongoing pregnancy |
| Iliodromiti 2015 (Hum Reprod Update) | SR/MA — performance characteristics | NR (multiple cohorts) | AMH/AFC technical performance | Sensitivity, specificity, AUC |
| Steiner 2017 (JAMA) | Prospective cohort | 750 | AMH and natural fecundity (no infertility) | Cumulative conception at 6 and 12 mo |
| Alviggi 2016 (Fertil Steril) | Expert consensus / criteria | NR | POSEIDON low-prognosis stratification | 4-subgroup framework |
| Esteves 2018 (Front Endocrinol) | Position paper | NR | POSEIDON criteria detailed definition | Subgroup-specific management |
| Humaidan 2016 (F1000Res) | Narrative review | NR | POSEIDON application | Outcome marker proposal |
| La Marca 2014 (Hum Reprod Update) | Narrative / pooled analysis | NR | Individualization of COS | Stimulation protocols by reserve |
| Nelson 2015 (Fertil Steril) | Multicenter cohort | 1,591 | AMH vs AFC in good-prognosis | Oocyte yield prediction |
| ASRM Practice Committee 2020 | Committee opinion | Synthesis | Testing interpretation framework | Recommendations |
| ACOG CO No. 781 (2019) | Committee opinion | Synthesis | Infertility workup framework | Counseling recommendations |
Key Findings — Synthesised by Theme
Theme 1 — AMH Reflects the Antral Follicle Pool, Not Oocyte Quality
AMH is produced by granulosa cells of preantral and small antral follicles and reflects the size of the ovarian follicle pool. Serum AMH declines progressively from early adulthood, with steeper declines after the late thirties, and becomes essentially undetectable after menopause. AMH ovarian reserve testing reflects follicle quantity, not oocyte quality — a critical distinction in counseling.
Modern automated AMH assays (Beckman Access, Roche Elecsys, Ansh Labs) have improved precision over earlier ELISA-based methods, but absolute values still differ between platforms. Threshold values used for clinical decision-making must be referenced to the specific assay used and to local laboratory normative data. The Iliodromiti 2015 review documents this assay-related heterogeneity in detail.
Theme 2 — AMH Predicts Poor and Hyper Response in IVF
The Broer 2011 meta-analysis pooled studies of AMH for excessive response prediction and reported pooled AUC around 0.81 for hyper response. The earlier Broer 2009 IPD meta-analysis (n=2,492) demonstrated AUC near 0.78 for poor response prediction. The Iliodromiti 2015 update added contemporary studies with similar performance estimates.
For poor response prediction, AMH thresholds typically below 0.5 to 1.0 ng/mL identify candidates for adjusted protocols, dose increase, or counseling toward alternative paths including oocyte donation. For hyper response prediction relevant to ovarian hyperstimulation syndrome (OHSS) risk, AMH thresholds above approximately 3.5 ng/mL identify patients in whom milder stimulation, antagonist regimens, and GnRH agonist trigger are favored.
The combined evidence supports AMH ovarian reserve testing as one of the strongest single biomarkers for IVF stimulation response. AMH performs comparably to antral follicle count in IPD meta-analyses, with AUCs typically within a few hundredths of a unit between the two markers.
Theme 3 — AMH Does Not Reliably Predict Natural Fecundity
AMH ovarian reserve testing does not reliably predict natural fecundity in women without diagnosed infertility. The Steiner 2017 JAMA prospective cohort followed 750 women aged 30 to 44 attempting natural conception. After adjustment for age and other factors, women with low AMH (below 0.7 ng/mL) showed similar cumulative probability of natural conception at 6 and 12 months compared with women with normal AMH.
This finding has reshaped counseling for women considering AMH ovarian reserve testing for general fertility planning. AMH remains useful for IVF planning, fertility preservation timing decisions, and identifying expected poor response, but should not be used as a stand-alone marker to advise women without infertility about their natural conception prospects.
The mechanistic explanation lies in what AMH measures. AMH reflects the antral follicle pool that is recruitable in a stimulation cycle, while natural conception depends on the dominant follicle and oocyte quality — phenomena that age-related decline tracks more closely than AMH does.
Theme 4 — POSEIDON Stratifies Low-Prognosis Patients Into 4 Subgroups
The POSEIDON criteria (Alviggi 2016, Esteves 2018) classify low-prognosis IVF patients into four subgroups based on age and ovarian reserve markers. The four groups are differentiated by whether age is below or at/above 35 years and whether AMH and AFC are within the normal range or low (typically AMH below 1.2 ng/mL or AFC below 5).
| POSEIDON Group | Age | AMH/AFC | Clinical Pattern |
|---|---|---|---|
| Group 1 | < 35 yr | Normal (AMH ≥ 1.2 ng/mL; AFC ≥ 5) | Unexpected poor response in prior cycle |
| Group 2 | ≥ 35 yr | Normal | Unexpected poor response in prior cycle |
| Group 3 | < 35 yr | Low (AMH < 1.2 ng/mL or AFC < 5) | Expected poor response (young + low reserve) |
| Group 4 | ≥ 35 yr | Low | Expected poor response (older + low reserve) |
The framework structures individualized management — including dose adjustment, dual stimulation across the same cycle (DuoStim), oocyte accumulation across cycles, and pre-implantation testing strategies — based on subgroup. POSEIDON has been operationalized in IVF programs across Europe, Latin America, and Asia, and informs ESHRE-aligned management discussions, although the subgroup-specific management benefit is supported by observational rather than RCT evidence.
Theme 5 — AMH Compares Favorably With FSH and AFC
AMH and antral follicle count show comparable predictive performance for IVF response. The Broer 2009 IPD analysis demonstrated similar AUCs for poor and hyper response prediction. The 2020 ASRM Practice Committee opinion positions AMH and AFC as the preferred biomarkers for ovarian reserve assessment.
Day-3 FSH retains a secondary role given its higher cycle-to-cycle variability and dependence on synchronous menstrual cycle timing. AMH ovarian reserve testing offers practical advantages: cycle-independent sampling, single blood draw, no need for transvaginal ultrasound, and stability of values over weeks. AFC requires skilled transvaginal ultrasound performed in the early follicular phase but provides direct visualization of the follicle pool.
Combining AMH and AFC adds modest incremental predictive value over either alone, supporting use of both markers in IVF planning when feasible. Adding patient age, body mass index, and prior cycle response further refines individualized prediction in models such as those described in the Broer 2013 IPD synthesis.
Clinical pearl — The single most important counseling distinction in AMH ovarian reserve testing is between IVF-context predictive value (well established) and natural-fecundity predictive value (not established). Communicating this distinction up front avoids misinterpretation of a low result.
AMH is typically elevated in PCOS — often above 4 to 5 ng/mL — reflecting the increased number of small antral follicles characteristic of polycystic ovarian morphology. Elevated AMH in PCOS is associated with hyper response risk, including OHSS, and supports milder stimulation regimens with antagonist protocols and GnRH agonist trigger. Some authors propose AMH thresholds (e.g., above 4.5 ng/mL on standardized assays) as supportive criteria for PCOS diagnosis, though guideline integration varies and PCOS diagnosis still rests on Rotterdam-style clinical and biochemical criteria.
AMH predicts live birth in IVF less robustly than it predicts ovarian response. Pooled estimates suggest modest discrimination for live birth (AUC typically in the 0.6 to 0.7 range), reflecting that age and embryo quality contribute substantially to live birth outcome beyond the oocyte yield that AMH predicts. AMH is most useful for cycle planning and counseling about expected response; live birth counseling should integrate age, prior cycle history, and embryo-related factors.
AMH ovarian reserve testing supports counseling and protocol selection for elective oocyte cryopreservation and oncofertility preservation. Lower AMH suggests the need for higher gonadotropin doses and may warrant counseling about expected oocyte yield per cycle. AMH can also inform timing decisions in patients considering preservation but not under acute time pressure. AMH does not predict the future age at menopause precisely enough to use as a stand-alone marker for “how soon to preserve” decisions.
Combined hormonal contraceptives modestly suppress serum AMH through gonadotropin-mediated reduction in small antral follicle activity, with reductions typically in the range of 15 to 30%. The suppression is reversible after contraceptive discontinuation. For accurate AMH ovarian reserve testing, the ASRM Practice Committee suggests interpreting values in the context of recent contraceptive exposure or, when possible, repeating measurement after a washout period.
Direct-to-consumer AMH testing is widely marketed for fertility planning, often without the IVF-context framing that supports the test’s validated clinical use. Patients may present with a low result and concerns about future natural fertility — concerns that the Steiner 2017 evidence does not support. Counseling should reframe AMH ovarian reserve testing in terms of what it predicts (IVF response and follicle pool size) and what it does not predict (natural conception probability in women without infertility).
Quality & Consistency of the Evidence
Evidence quality across the AMH ovarian reserve literature is high for the central question of IVF response prediction and for the natural fecundity finding from Steiner 2017. The Broer IPD meta-analyses, the Iliodromiti 2015 update, and the ASRM 2020 Practice Committee opinion provide the principal evidence framework.
What the Evidence Does Not Show
Several specific gaps remain in the AMH ovarian reserve evidence base. Naming these gaps explicitly is more useful than the generic “more research is needed” framing.
Specific evidence gaps
- Inter-assay standardization remains incomplete — different automated platforms produce non-interchangeable absolute values, limiting universal threshold definitions and complicating cross-study comparisons.
- Live birth prediction by AMH ovarian reserve testing is more modest than ovarian response prediction (pooled AUC typically 0.6 to 0.7 for live birth), and AMH should not be used as a stand-alone live birth predictor.
- Reference ranges in adolescents, ethnic minorities, and across global populations are not as well characterized as in the predominantly North American and European cohorts that anchor the meta-analyses.
- Long-term reproductive lifespan and age-at-menopause prediction by AMH have moderate but imprecise discrimination — AMH narrows the menopause-timing window but cannot specify it precisely enough for individual decision-making.
- RCTs of POSEIDON-guided management versus standard care for live birth outcomes are limited; subgroup-specific stimulation strategies are supported by observational data and expert consensus.
- Interpretation of AMH after recent or current hormonal contraceptive exposure, GnRH agonist therapy, or recent ovarian surgery requires context that pivotal validation studies did not always include.
In addition, AMH interpretation in patients with prior chemotherapy, radiation, autoimmune oophoritis, and Turner mosaicism is supported by smaller observational series rather than systematic comparative cohorts. Clinical decisions in these subpopulations rely on integrating AMH with patient history and direct AFC assessment.
Practical Implications for AMH Ovarian Reserve Testing
Based on the current evidence, the following considerations may inform AMH ovarian reserve testing practice. These are framed as evidence-based considerations rather than directive recommendations; clinical context, fertility goals, and individual patient circumstances should guide decisions.
Implementation should be tailored to the clinical context — IVF planning, fertility preservation timing, oncofertility counseling, or evaluation of suspected primary ovarian insufficiency. AMH ovarian reserve testing is best framed as one input into individualized counseling rather than a stand-alone diagnostic, and should always be integrated with patient age, history, and (when appropriate) AFC and clinical examination.
Evidence Grade & Bottom Line
Overall Evidence Grade — Strong (for IVF response prediction, AMH/AFC equivalence, and the Steiner 2017 natural fecundity finding); Moderate (for POSEIDON framework, fertility preservation counseling); Limited (for inter-assay standardization, live birth prediction as stand-alone, and adolescent/global reference ranges). The body of evidence supporting current AMH ovarian reserve testing applications is unlikely to shift fundamentally with further research, although assay standardization and POSEIDON RCT validation remain active areas.
Bottom Line
- AMH ovarian reserve testing is a validated biomarker of antral follicle pool size and IVF response, not of natural fecundity in unselected women.
- Pooled meta-analyses support AMH for predicting poor and hyper response in IVF, with AUC around 0.78 for poor response prediction.
- The POSEIDON criteria classify low-prognosis IVF patients into 4 subgroups based on age and ovarian reserve markers, structuring individualized stimulation strategy.
- AMH and antral follicle count have comparable predictive performance; AMH offers practical advantages of cycle independence and single blood draw.
- The Steiner 2017 JAMA finding that AMH does not reliably predict natural fecundity is a critical counseling point, particularly given direct-to-consumer AMH marketing.
Article Information & References
For Educational Purposes Only
This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Test interpretation thresholds should be referenced to the specific assay used and to the most recent ASRM and ACOG practice documents.
References
- Broer SL, Mol BW, Hendriks D, Broekmans FJ. The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil Steril. 2009;91(3):705–714. DOI: 10.1016/j.fertnstert.2007.12.013
- Broer SL, Dólleman M, Opmeer BC, Fauser BC, Mol BW, Broekmans FJ. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Hum Reprod Update. 2011;17(1):46–54. DOI: 10.1093/humupd/dmq034
- Broer SL, van Disseldorp J, Broeze KA, et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update. 2013;19(1):26–36. DOI: 10.1093/humupd/dms041
- Iliodromiti S, Anderson RA, Nelson SM. Technical and performance characteristics of anti-Müllerian hormone and antral follicle count as biomarkers of ovarian response. Hum Reprod Update. 2015;21(6):698–710. DOI: 10.1093/humupd/dmu062
- Steiner AZ, Pritchard D, Stanczyk FZ, et al. Association Between Biomarkers of Ovarian Reserve and Infertility Among Older Women of Reproductive Age. JAMA. 2017;318(14):1367–1376. DOI: 10.1001/jama.2017.14588
- Alviggi C, Andersen CY, Buehler K, et al. A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril. 2016;105(6):1452–1453. DOI: 10.1016/j.fertnstert.2016.02.005
- Esteves SC, Roque M, Bedoschi GM, et al. Defining Low Prognosis Patients Undergoing Assisted Reproductive Technology: POSEIDON Criteria — The Why. Front Endocrinol. 2018;9:461. DOI: 10.3389/fendo.2018.00461
- Humaidan P, Alviggi C, Fischer R, Esteves SC. The novel POSEIDON stratification of ‘Low prognosis patients in Assisted Reproductive Technology’ and its proposed marker of successful outcome. F1000Res. 2016;5:2911. DOI: 10.12688/f1000research.10382.1
- La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update. 2014;20(1):124–140. DOI: 10.1093/humupd/dmt037
- Nelson SM, Klein BM, Arce JC. Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials. Fertil Steril. 2015;103(4):923–930.e1. DOI: 10.1016/j.fertnstert.2014.12.114
- Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2020;114(6):1151–1157. DOI: 10.1016/j.fertnstert.2020.09.134
- American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 781: Infertility Workup for the Women’s Health Specialist. Obstet Gynecol. 2019;133(6):e377–e384. DOI: 10.1097/AOG.0000000000003271
- Depmann M, Eijkemans MJC, Broer SL, et al. Does AMH relate to timing of menopause? Results of an individual patient data meta-analysis. J Clin Endocrinol Metab. 2018;103(10):3593–3600. DOI: 10.1210/jc.2018-00724